文献速递肿瘤 PET/CT

68Ga-PSMA-11 PET/CT在根治性治疗后生化复发前列腺癌不同临床阶段中的效能

68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-10-22

该前瞻性单中心试验纳入332例根治性治疗后生化复发(PSA 0.2-2 ng/ml)前列腺癌患者,评估68Ga-PSMA-11 PET/CT检出率。总检出率为53.6%(95%CI 48.1%-59.1%),不同生化复发临床阶段检出率不同(亚组1 64.5%、亚组2 45.6%、亚组3 58.7%),阳性预测值为96.2%。

要点

  • 68Ga-PSMA-11 PET/CT总检出率53.6%(95%CI 48.1%-59.1%)。
  • 盆腔局限病灶检出24.7%,远处病灶检出28.9%。
  • 不同生化复发阶段检出率:亚组1 64.5%、亚组2 45.6%、亚组3 58.7%。

核心结论

  • 数据证实68Ga-PSMA-11 PET/CT对根治性治疗后PSA失败患者检测局部与全身性疾病有效。
  • 68Ga-PSMA-11 PET/CT检出率依生化复发临床阶段不同而异,转诊医生应考虑此信息。

研究设计与样本

  • 前瞻性、开放标签、单中心试验,于博洛尼亚大学医院核医学科进行(Eudract: 2015-004589-27 OsSC)。
  • 纳入332例患者,2016年3月至2017年6月入组;平均/中位PSA为0.84/0.61 ng/ml。
  • 97.9%(325/332)患者接受根治性前列腺切除术,2.1%(7/332)接受放疗。
  • 生化复发模式分为:亚组1(根治性前列腺切除术后持续可检测PSA)13.5%(45/332);亚组2(根治性治疗后首次PSA失败)44.9%(149/332);亚组3(挽救性或激素治疗后PSA升高)41.6%(138/332)。

主要发现

  • 68Ga-PSMA-11 PET/CT总检出率为53.6%(95%CI 48.1%-59.1%)。
  • 基于患者的分析中,疾病局限于盆腔(前列腺床和/或淋巴结)者占24.7%(82/332)。
  • 至少一个远处病灶者占28.9%(96/332)。
  • 不同亚组检出率:亚组1为64.5%,亚组2为45.6%,亚组3为58.7%。
  • PSA(p=0.041)和PSA倍增时间(PSAdt,p=0.001)与68Ga-PSMA-11 PET/CT检出率相关。

关键数值与推荐

  • 纳入标准:确诊前列腺癌、手术或放疗为确定性治疗、确诊生化复发、PSA 0.2-2 ng/ml、年龄≥35岁、愿意签署知情同意。
  • 68Ga-PSMA-11 PET/CT阳性时,对照影像学检查阴性者占83%(108/130)。
  • 计算得出的阳性预测值(PPV)为96.2%。
  • 对照影像学检查可获取者占73.2%(243/332)。

临床怎么用

  • 68Ga-PSMA-11 PET/CT可用于根治性治疗后PSA失败患者检测局部与全身性疾病。
  • 转诊医生应考虑生化复发临床阶段对68Ga-PSMA-11 PET/CT检出率的影响。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The primary objective was the evaluation of Gallium 68 (68Ga)-prostate-specific membrane antigen (PSMA)-11 positron emission tomography/computed tomography (PET/CT) detection rate, for identifying the site of prostate cancer (PCa) relapse (local vs systemic), stratifying the population according to different clinical stages of biochemical recurrence (BCR). Secondary aims were: 1) to evaluate the association of clinical/pathologic features and 68Ga-PSMA-11 PET/CT detection rate, 2) to compare 68Ga-PSMA-11 PET/CT with other imaging procedures, and 3) to evaluate the positive predictive value (PPV) in a per-patient analysis. MATERIAL AND METHODS: This population was enrolled through a prospective, open label, single-center trial performed at the Nuclear Medicine of the University Hospital of Bologna (Eudract: 2015-004589-27 OsSC). The inclusion criteria were: (1) proven PCa, (2) surgery or radiotherapy as definitive therapy, (3) proven BCR, (4) prostate-specific antigen (PSA) 0.2-2 ng/ml, (5) age ≥ 35 years, and 6() willing to sign an informed consent. Three-hundred and thirty-two (332) patients were enrolled between March 2016 and June 2017; mean/median PSA was 0.84/0.61 ng/ml, 97.9% (325/332) of patients received radical prostatectomy and 2.1% (7/332) radiotherapy. Different patterns of BCR were identified by referent physicians as follows: (a) persisting detectable PSA after radical prostatectomy in 13.5% (45/332) of patients (subgroup 1), (b) first-time PSA failure after radical therapy in 44.9% (149/332) (subgroup 2), and (c) PSA increase after salvage or hormonal therapy in 41.6% (138/332) (subgroup 3). RESULTS: Primary objective: 68Ga-PSMA-11 PET/CT detection rate was 53.6% (CI 95% 48.1%-59.1%). In a patient-based analysis, disease confined to pelvis (prostate bed and/or lymph-nodes) was detected in 24.7% of cases (82/332). The presence of at least one distant lesion was observed in 28.9% of cases (96/332). The detection rate in different subgroups was: subgroup 1 = 64.5%, subgroup 2 = 45.6%, and subgroup-3 = 58.7%. Secondary objectives: 1) PSA (p = 0.041) and PSAdt (p = 0.001) showed association with 68Ga-PSMA-11 PET/CT detection rate, and 2) correlative imaging was available in 73.2% of patients (243/332). When 68Ga-PSMA-11 PET/CT was positive, correlative imaging resulted negative in 83% of cases (108/130). 3) The calculated PPV was 96.2%. CONCLUSION: Our data confirmed the efficacy of 68Ga-PSMA-11 PET/CT for detecting local vs systemic disease in PCa patients presenting PSA failure after radical therapy. Furthermore, 68Ga-PSMA-11 PET/CT detection rate is different depending on the clinical stage of BCR, and this information should be taken into consideration by referring physicians.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ceci F, Castellucci P, Graziani T, et al. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging. 2018. PMID: 30350010. doi:10.1007/s00259-018-4189-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。